Yunjie Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yunjie Wang has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Jingwei Tian
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China
6 shared publications - Xiaohui Sun
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong Yantai University Yantai Shandong People's Republic of China
4 shared publications - Jianzhao Zhang
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China
3 shared publications - Gangqiang Yang
School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai, 264005, China
2 shared publications Jianzhao Zhang
Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), School of Pharmacy, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University
2 shared publications- Runchen Ma
Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, School of Pharmacy, Yantai University, Yantai 264005, China
2 shared publications
Latest Publications
- Open Access
Cuproptosis in Ischemic Stroke: Molecular Mechanisms and Therapeutic Potential
Stroke is a major neurological disease caused by cerebral vascular obstruction or rupture and represents a leading cause of death and long-term disability worldwide. Ischemic stroke (IS) accounts for the majority of stroke cases, while effective therapeutic strategies remain limited. Therefore, a better understanding of the underlying pathological mechanisms and the identification of new therapeutic targets are urgently needed. Cerebral ischemia triggers various regulated forms of cell death, including apoptosis, ferroptosis, and cuproptosis, which was discovered in recent years. Emerging evidence suggests that copper imbalance and copper-dependent cell death may play important roles in the development and progression of IS. This review summarizes the molecular mechanisms of cuproptosis and its potential involvement in cerebral ischemia, and discusses the therapeutic potential of cuproptosis-targeting agents for improving neurological outcomes after stroke.
Open AccessCuproptosis in Ischemic Stroke: Molecular Mechanisms and Therapeutic Potential
Stroke is a major neurological disease caused by cerebral vascular obstruction or rupture and represents a leading cause of death and long-term disability worldwide. Ischemic stroke (IS) accounts for the majority of stroke cases, while effective therapeutic strategies remain limited. Therefore, a better understanding of the underlying pathological mechanisms and the identification of new therapeutic targets are urgently needed. Cerebral ischemia triggers various regulated forms of cell death, including apoptosis, ferroptosis, and cuproptosis, which was discovered in recent years. Emerging evidence suggests that copper imbalance and copper-dependent cell death may play important roles in the development and progression of IS. This review summarizes the molecular mechanisms of cuproptosis and its potential involvement in cerebral ischemia, and discusses the therapeutic potential of cuproptosis-targeting agents for improving neurological outcomes after stroke.
- Open Access
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1759454
TAAR1-mediated pathways regulating nigrostriatal function and the discovery and pharmacological characterization of a novel TAAR1 agonist, Selutaront
Introduction: Schizophrenia is a severe neurodevelopmental disorder with limited treatment options. Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target, yet its downstream signaling mechanisms and the development of highly selective agonists remain incompletely explored. Methods: In this study, we established a TAAR1 knockdown rat model to elucidate its role in movement regulation and downstream signaling. Through molecular docking, site-directed mutagenesis and functional tests, we identified and characterized a novel TAAR1 agonist - Selutaront. We evaluated its antipsychotic-like effects in a mouse model similar to schizophrenia induced by MK-801 and identified its potential mechanism. Finally, we conducted pharmacokinetic analysis, Caco-2 permeability tests and liver microsomal stability tests to assess its drugability. Results: The research results indicate that TAAR1 mainly regulates the functional integrity of the substantia nigra-striatum circuit through the cAMP/PKA/CREB and DARPP32 signaling axes. Selutaront is a highly selective TAAR1 agonist, which forms a crucial interaction with the residues Asp103, Phe267, and Ser107 in the binding pocket. In vivo, Selutaront dose-dependently alleviates the schizophrenia-like behaviors induced by MK-801 in mice and counteracts the downregulation of the PKA/CREB pathway. Moreover, it exhibits excellent pharmacokinetic properties. Conclusion: This study demonstrates that TAAR1 regulates nigrostriatal function primarily via the PKA/CREB/DARPP32 signaling axis. Selutaront, a novel highly selective TAAR1 agonist with favorable drug-like properties, represents a promising candidate for schizophrenia treatment and provides mechanistic insights into TAAR1-targeted therapy.
- 23 February 2026
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1759454
Open AccessTAAR1-mediated pathways regulating nigrostriatal function and the discovery and pharmacological characterization of a novel TAAR1 agonist, Selutaront
Introduction: Schizophrenia is a severe neurodevelopmental disorder with limited treatment options. Trace amine-associated receptor 1 (TAAR1) has emerged as a promising therapeutic target, yet its downstream signaling mechanisms and the development of highly selective agonists remain incompletely explored. Methods: In this study, we established a TAAR1 knockdown rat model to elucidate its role in movement regulation and downstream signaling. Through molecular docking, site-directed mutagenesis and functional tests, we identified and characterized a novel TAAR1 agonist - Selutaront. We evaluated its antipsychotic-like effects in a mouse model similar to schizophrenia induced by MK-801 and identified its potential mechanism. Finally, we conducted pharmacokinetic analysis, Caco-2 permeability tests and liver microsomal stability tests to assess its drugability. Results: The research results indicate that TAAR1 mainly regulates the functional integrity of the substantia nigra-striatum circuit through the cAMP/PKA/CREB and DARPP32 signaling axes. Selutaront is a highly selective TAAR1 agonist, which forms a crucial interaction with the residues Asp103, Phe267, and Ser107 in the binding pocket. In vivo, Selutaront dose-dependently alleviates the schizophrenia-like behaviors induced by MK-801 in mice and counteracts the downregulation of the PKA/CREB pathway. Moreover, it exhibits excellent pharmacokinetic properties. Conclusion: This study demonstrates that TAAR1 regulates nigrostriatal function primarily via the PKA/CREB/DARPP32 signaling axis. Selutaront, a novel highly selective TAAR1 agonist with favorable drug-like properties, represents a promising candidate for schizophrenia treatment and provides mechanistic insights into TAAR1-targeted therapy.
- Open Access
- 23 December 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (24) , e70526
Inhibitory Effect of PRMT5/MTA Inhibitor on MTAP‐Deficient Glioma May Be Influenced by Surrounding Normal Cells
Background: Methylthioadenosine phosphorylase (MTAP) and protein arginine methyltransferase 5 (PRMT5) are considered to be a synthetic lethal pair of targets, due to the fact that deletion of MTAP leads to massive production of methylthioadenosine (MTA) decreasing the activity of PRMT5. In vitro and in vivo experiments have demonstrated that MRTX1719, a small molecule that selectively binds PRMT5/MTA complex, significantly inhibits the proliferation of MTAP‐deficient tumors and has a weak toxic effect on normal cells. However, it has been reported that MTAP‐deleted tumors did not significantly accumulate MTA in vivo due to metabolism of MTA by MTAP‐expressing stroma, which might lead to a diminished anti‐cancer effect of MRTX1719.Methods: We first analyzed whether there were MTAP‐expressing normal intracerebral cells around MTAP‐deficient glioma tissues by paraffin‐embedded tissue microarray of human glioma specimens. Then, in vivo and in vitro models of MTAP‐deficient gliomas coexisting with neurons or glial cells were constructed for evaluating the effectiveness of the anti‐tumor effects of MRTX1719 in this setting.Results: MTAP‐deficient gliomas were surrounded by a large number of MTAP‐expressing normal cells, and the presence of these cells significantly reduced the inhibitory effect of MRTX1719 on MTAP‐deficient glioma cells in vitro and in vivo.Conclusions: Due to the complexity of the tumor environment in vivo, the anti‐tumor effects of PRMT5/MTA‐specific inhibitors may be somewhat attenuated, and their ability to achieve suitable therapeutic effects in the clinic might require more in‐depth studies.
- 23 December 2024
- Published by Wiley in Cancer Medicine
- Vol. 13 (24) , e70526
Open AccessInhibitory Effect of PRMT5/MTA Inhibitor on MTAP‐Deficient Glioma May Be Influenced by Surrounding Normal Cells
Background: Methylthioadenosine phosphorylase (MTAP) and protein arginine methyltransferase 5 (PRMT5) are considered to be a synthetic lethal pair of targets, due to the fact that deletion of MTAP leads to massive production of methylthioadenosine (MTA) decreasing the activity of PRMT5. In vitro and in vivo experiments have demonstrated that MRTX1719, a small molecule that selectively binds PRMT5/MTA complex, significantly inhibits the proliferation of MTAP‐deficient tumors and has a weak toxic effect on normal cells. However, it has been reported that MTAP‐deleted tumors did not significantly accumulate MTA in vivo due to metabolism of MTA by MTAP‐expressing stroma, which might lead to a diminished anti‐cancer effect of MRTX1719.Methods: We first analyzed whether there were MTAP‐expressing normal intracerebral cells around MTAP‐deficient glioma tissues by paraffin‐embedded tissue microarray of human glioma specimens. Then, in vivo and in vitro models of MTAP‐deficient gliomas coexisting with neurons or glial cells were constructed for evaluating the effectiveness of the anti‐tumor effects of MRTX1719 in this setting.Results: MTAP‐deficient gliomas were surrounded by a large number of MTAP‐expressing normal cells, and the presence of these cells significantly reduced the inhibitory effect of MRTX1719 on MTAP‐deficient glioma cells in vitro and in vivo.Conclusions: Due to the complexity of the tumor environment in vivo, the anti‐tumor effects of PRMT5/MTA‐specific inhibitors may be somewhat attenuated, and their ability to achieve suitable therapeutic effects in the clinic might require more in‐depth studies.
- Open Access
LPM682000012, a Synthetic Neuroactive Steroid That Ameliorates Epileptic Seizures by Downregulating the Serpina3n/NF-κB Signaling Pathway
Epilepsy is characterized by abnormal neuronal firing in the brain. Several therapeutic strategies exist for epilepsy; however, several patients remain poorly treated. Therefore, the development of effective treatments remains a high priority in the field. Neuroactive steroids can potentiate extra-synaptic and synaptic GABAA receptors, thereby providing therapeutic benefits relative to benzodiazepines. This research study investigated the therapeutic effectiveness and underlying mechanisms of LPM682000012, a new synthetic neuroactive steroid-positive allosteric modulator (PAM) of GABAA receptors employed for treating epilepsy. Acute and chronic rat epilepsy models were established to identify the anti-seizure potency of LPM682000012. The dose-dependent sedative effects of LPM682000012 and Ganaxolone in normal rats were evaluated, which revealed that they both dose-dependently alleviated acute epileptic seizure in the pentylenetetrazol (PTZ)-mediated seizure model. Furthermore, LPM682000012 indicated an enhanced safety profile than Ganaxolone. Moreover, LPM682000012 also indicated therapeutic effects in the kainic acid (KA)-induced chronic spontaneous seizure model. Morphologically, LPM682000012 decreased neuronal loss in the hippocampal CA1 and CA3 regions and increased dendritic spine density in the CA1 region. In addition, mechanical analyses, including transcriptomics, Western blot, and proteomics analyses, revealed that the Serpina3n/NF-κB signaling pathway was up-regulated in epileptic rat hippocampal tissue, and LPM682000012 treatment reversed these changes. In summary, this report demonstrated that the novel neurosteroid GABAA PAM LPM682000012 activated the synaptic and extra-synaptic GABAA receptors and alleviated KA-induced neuronal loss and synaptic remodeling, potentially by down-regulating the Serpina3n/NF-κB signaling pathways. The results provide evidence that LPM682000012 is a potential anti-seizure pharmacotherapy candidate for epilepsy and warrants further research.
Open AccessLPM682000012, a Synthetic Neuroactive Steroid That Ameliorates Epileptic Seizures by Downregulating the Serpina3n/NF-κB Signaling Pathway
Epilepsy is characterized by abnormal neuronal firing in the brain. Several therapeutic strategies exist for epilepsy; however, several patients remain poorly treated. Therefore, the development of effective treatments remains a high priority in the field. Neuroactive steroids can potentiate extra-synaptic and synaptic GABAA receptors, thereby providing therapeutic benefits relative to benzodiazepines. This research study investigated the therapeutic effectiveness and underlying mechanisms of LPM682000012, a new synthetic neuroactive steroid-positive allosteric modulator (PAM) of GABAA receptors employed for treating epilepsy. Acute and chronic rat epilepsy models were established to identify the anti-seizure potency of LPM682000012. The dose-dependent sedative effects of LPM682000012 and Ganaxolone in normal rats were evaluated, which revealed that they both dose-dependently alleviated acute epileptic seizure in the pentylenetetrazol (PTZ)-mediated seizure model. Furthermore, LPM682000012 indicated an enhanced safety profile than Ganaxolone. Moreover, LPM682000012 also indicated therapeutic effects in the kainic acid (KA)-induced chronic spontaneous seizure model. Morphologically, LPM682000012 decreased neuronal loss in the hippocampal CA1 and CA3 regions and increased dendritic spine density in the CA1 region. In addition, mechanical analyses, including transcriptomics, Western blot, and proteomics analyses, revealed that the Serpina3n/NF-κB signaling pathway was up-regulated in epileptic rat hippocampal tissue, and LPM682000012 treatment reversed these changes. In summary, this report demonstrated that the novel neurosteroid GABAA PAM LPM682000012 activated the synaptic and extra-synaptic GABAA receptors and alleviated KA-induced neuronal loss and synaptic remodeling, potentially by down-regulating the Serpina3n/NF-κB signaling pathways. The results provide evidence that LPM682000012 is a potential anti-seizure pharmacotherapy candidate for epilepsy and warrants further research.
- Open Access
Ferroptosis in Ischemic Stroke and Related Traditional Chinese Medicines
Stroke is a severe neurological disorder resulting from the rupture or blockage of blood vessels, leading to significant mortality and disability worldwide. Among the different types of stroke, ischemic stroke (IS) is the most prevalent, accounting for 70–80% of cases. Cell death following IS occurs through various mechanisms, including apoptosis, necrosis, and ferroptosis. Ferroptosis, a recently identified form of regulated cell death characterized by iron overload and lipid peroxidation, was first described by Dixon in 2012. Currently, the only approved pharmacological treatment for IS is recombinant tissue plasminogen activator (rt-PA), which is limited by a narrow therapeutic window and often results in suboptimal outcomes. Recent research has identified several traditional Chinese medicines (TCMs) that can inhibit ferroptosis, thereby mitigating the damage caused by IS. This review provides an overview of stroke, the role of ferroptosis in IS, and the potential of certain TCMs to inhibit ferroptosis and contribute to stroke treatment.
Open AccessFerroptosis in Ischemic Stroke and Related Traditional Chinese Medicines
Stroke is a severe neurological disorder resulting from the rupture or blockage of blood vessels, leading to significant mortality and disability worldwide. Among the different types of stroke, ischemic stroke (IS) is the most prevalent, accounting for 70–80% of cases. Cell death following IS occurs through various mechanisms, including apoptosis, necrosis, and ferroptosis. Ferroptosis, a recently identified form of regulated cell death characterized by iron overload and lipid peroxidation, was first described by Dixon in 2012. Currently, the only approved pharmacological treatment for IS is recombinant tissue plasminogen activator (rt-PA), which is limited by a narrow therapeutic window and often results in suboptimal outcomes. Recent research has identified several traditional Chinese medicines (TCMs) that can inhibit ferroptosis, thereby mitigating the damage caused by IS. This review provides an overview of stroke, the role of ferroptosis in IS, and the potential of certain TCMs to inhibit ferroptosis and contribute to stroke treatment.
- Open Access
Discovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53
Cell cycle-dependent kinase 2 (CDK2) is located downstream of CDK4/6 in the cell cycle and regulates cell entry into S-phase by binding to Cyclin E and hyper-phosphorylating Rb. Proto-oncogene murine double minute 2 (MDM2) is a key negative regulator of p53, which is highly expressed in tumors and plays an important role in tumorigenesis and progression. In this study, we identified a dual inhibitor of CDK2 and MDM2, III-13, which had good selectivity for inhibiting CDK2 activity and significantly reduced MDM2 expression. In vitro results showed that III-13 inhibited proliferation of a wide range of tumor cells, regardless of whether Cyclin E1 (CCNE1) was overexpressed or not. The results of in vivo experiments showed that III-13 significantly inhibited proliferation of tumor cells and did not affect body weight of mice. The results of the druggability evaluation showed that III-13 was characterized by low bioavailability and poor membrane permeability when orally administered, suggesting the necessity of further structural modifications. Therefore, this study provided a lead compound for antitumor drugs, especially those against CCNE1-amplified tumor proliferation.
Open AccessDiscovery of Novel Antitumor Small-Molecule Agent with Dual Action of CDK2/p-RB and MDM2/p53
Cell cycle-dependent kinase 2 (CDK2) is located downstream of CDK4/6 in the cell cycle and regulates cell entry into S-phase by binding to Cyclin E and hyper-phosphorylating Rb. Proto-oncogene murine double minute 2 (MDM2) is a key negative regulator of p53, which is highly expressed in tumors and plays an important role in tumorigenesis and progression. In this study, we identified a dual inhibitor of CDK2 and MDM2, III-13, which had good selectivity for inhibiting CDK2 activity and significantly reduced MDM2 expression. In vitro results showed that III-13 inhibited proliferation of a wide range of tumor cells, regardless of whether Cyclin E1 (CCNE1) was overexpressed or not. The results of in vivo experiments showed that III-13 significantly inhibited proliferation of tumor cells and did not affect body weight of mice. The results of the druggability evaluation showed that III-13 was characterized by low bioavailability and poor membrane permeability when orally administered, suggesting the necessity of further structural modifications. Therefore, this study provided a lead compound for antitumor drugs, especially those against CCNE1-amplified tumor proliferation.